PD-1 inhibitors versus chemotherapy as second-line treatment for advanced esophageal squamous cell carcinoma: a meta-analysis
Abstract Background Aim to establish the inhibitors of programmed cell death protein 1 (PD-1) as second-line therapy for advanced esophageal squamous cell carcinoma (ESCC). Methods Published clinical trials in the PubMed, Medline, Embase databases on PD-1 inhibitors for the treatment of ESCC were se...
Guardado en:
Autores principales: | Xinxin Zhu, Qiyue Shanzhou, Danyang Li, Xuezhou Pang, Daiyuan Ma |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
BMC
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/824d633b0da4415d9f2c220a391921ed |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma
por: Hongfu Cai, et al.
Publicado: (2021) -
Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study
por: Peng Yang, et al.
Publicado: (2021) -
New Trend of Surgery in Locally Advanced Esophageal Squamous Cell Carcinoma Patients
por: Tatcha Rerkrak, et al.
Publicado: (2021) -
Characterization of Esophageal Microbiota in Patients With Esophagitis and Esophageal Squamous Cell Carcinoma
por: Zongdan Jiang, et al.
Publicado: (2021) -
Metformin Downregulates PD-L1 Expression in Esophageal Squamous Cell Catrcinoma by Inhibiting IL-6 Signaling Pathway
por: Yao Lu, et al.
Publicado: (2021)